Niwa Toshiro, Inoue Sachiko, Shiraga Toshifumi, Takagi Akira
Post-marketing Development Research Center, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Biol Pharm Bull. 2005 Jan;28(1):188-91. doi: 10.1248/bpb.28.188.
The effects of sulpiride, an antipsychotic drug, on cytochrome P450 (CYP) activities in human liver microsomes were investigated. Sulpiride at 50 or 500 microM concentration neither inhibited nor stimulated CYP1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, or CYP3A4-mediated testosterone 6beta-hydroxylation. The free fractions of sulpiride in the incubation mixture estimated by ultracentrifugation were more than 90.5%. These results suggest that sulpiride would not cause clinically significant interactions with other drugs, which are metabolized by CYPs, via the inhibition of metabolism.
研究了抗精神病药物舒必利对人肝微粒体中细胞色素P450(CYP)活性的影响。50或500微摩尔浓度的舒必利既不抑制也不刺激CYP1A2介导的7-乙氧基试卤灵O-脱乙基、CYP2C9介导的甲苯磺丁脲羟基化、CYP2C19介导的S-美芬妥因4'-羟基化、CYP2D6介导的异喹胍4-羟基化、CYP2E1介导的氯唑沙宗6-羟基化、CYP3A4介导的硝苯地平氧化或CYP3A4介导的睾酮6β-羟基化。通过超速离心估计的孵育混合物中舒必利的游离分数超过90.5%。这些结果表明,舒必利不会通过抑制代谢与其他经CYPs代谢的药物产生临床上显著的相互作用。